RA Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

RA Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.6M	Hold	8,340,508	–	–	0.12%	72
2025 Q4	$20.1M	Hold	8,340,508	–	–	0.21%	49
2025 Q3	$15.1M	Hold	8,340,508	–	–	0.19%	48
2025 Q2	$9.93M	Hold	8,340,508	–	–	0.17%	46
2025 Q1	$16.9M	Hold	8,340,508	–	–	0.28%	48
2024 Q4	$50.2M	Hold	8,340,508	–	–	0.67%	31
2024 Q3	$58.4M	Hold	8,340,508	–	–	0.67%	33
2024 Q2	$48.4M	Buy	8,340,508 +3,530,000	+73%	+$28.4M	0.64%	39
2024 Q1	$34.4M	Hold	4,810,508	–	–	0.44%	49
2023 Q4	$23.7M	Hold	4,810,508	–	–	0.37%	44
2023 Q3	$46M	Hold	4,810,508	–	–	0.91%	33
2023 Q2	$62.3M	Hold	4,810,508	–	–	1.18%	26
2023 Q1	$61M	Hold	4,810,508	–	–	1.38%	25
2022 Q4	$55.4M	Buy	+4,810,508	New	+$61.1M	1.12%	26

Other funds holding ACRV

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RA Capital Management's ACRV Position: Q1 2026 in Review

RA Capital Management held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 8,340,508 shares worth $11.6M. The position accounts for 0.12% of the portfolio, ranked #72.

RA Capital Management first reported a position in ACRV in Q4 2022 and has held it in 14 quarters since. The position peaked at $62.3M in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

RA Capital Management held 8,340,508 shares of Acrivon Therapeutics worth $11.6M as of Q1 2026.
RA Capital Management left its Acrivon Therapeutics share count unchanged in Q1 2026.
Acrivon Therapeutics made up 0.12% of RA Capital Management's portfolio in Q1 2026, its #72 holding.
RA Capital Management first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 14 quarters since.
RA Capital Management's Acrivon Therapeutics position peaked at $62.3M in Q2 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.